4[4]Gleiter CH,Morike KE.Clinical pharmacokinetics of candesartan[J].Clin Pharmacokinet,2002,41(1):7.
5[5]Balt JC,Mathy MJ,Nap A,et al.Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery[J].J Cardiovasc Pharmacol,2002,40(1):50.
6[6]Dendorfer A,Raasch W,Tempel K,et al.Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat[J].J Hypertens,2002,20(6):1151.
7[7]Goineau S,Nisse-Durgeat S,Pape D,et al.Systemic and regional hemodynamic and cardiac remodeling effects of candesartan in dilated cardiomyopathic hamsters with advanced congestive heart failure[J].J Cardiovasc Pharmacol,2002,40(2):189.
8[8]Gohlke P,Kox T,Jurgensen T,et al.Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats[J].Naunyn Schmiedebergs Arch Pharmacol,2002,365(6):477.
9[9]Nakaya H,Sasamura H,Hayashi M,et al.Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis[J].J Am Soc Nephrol,2001,12 (4):659.
10[10]Naito Y,Tsujino T,Fujioka Y,et al.Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats[J].Hypertension,2002,40(6):827.
